{
    "clinical_study": {
        "@rank": "151251", 
        "arm_group": {
            "arm_group_label": "Denileukin Diftitox Plus Subcutaneous Pegylated IFN\u03b1-2A", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will test the hypothesis that adding pegylated IFN (IFN)a-2b to denileukin\n      diftitox improves the potential of denileukin diftitox alone to deplete regulatory T cells\n      (Tregs) and will thereby boost tumor immunity in patients with advanced-stage epithelial\n      ovarian cancers, enhancing treatment efficacy."
        }, 
        "brief_title": "A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFN\u03b1-2A in Stage III or IV Ovarian Cancer", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Denileukin Diftitox Plus Subcutaneous Pegylated IFN\u03b1-2a :", 
                        "title": "Denileukin Diftitox Plus Subcutaneous Pegylated IFN\u03b1-2A"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "2"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "<=18 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "2"
                                            }
                                        }, 
                                        "sub_title": "Between 18 and 65 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": ">=65 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "3", 
                                            "@value": "57"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "2"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "2"
                                        }
                                    }, 
                                    "sub_title": "United States"
                                }
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed."
            }, 
            "outcome_list": {
                "outcome": {
                    "description": "Although positive clinical response criteria are based on RECIST criteria, failure to respond criteria are not based on RECIST criteria, which have unclear application to immune-based clinical trials. Instead, novel lack-of-failure criteria, rather than failure-of-success criteria have been written to avoid stopping therapy prematurely without compromising patient safety, to accommodate the uncertainties of assessing failure in this setting. The criteria as written are based on sound medical, scientific and ethical principles. The trial is further designed to help establish the utility of these novel criteria.", 
                    "group_list": {
                        "group": {
                            "@group_id": "O1", 
                            "description": "Denileukin Diftitox Plus Subcutaneous Pegylated IFN\u03b1-2a :", 
                            "title": "Denileukin Diftitox Plus Subcutaneous Pegylated IFN\u03b1-2A"
                        }
                    }, 
                    "measure_list": {
                        "measure": [
                            {
                                "category_list": {
                                    "category": {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "O1", 
                                                "@value": "2"
                                            }
                                        }
                                    }
                                }, 
                                "param": "Number", 
                                "title": "Number of Participants", 
                                "units": "participants"
                            }, 
                            {
                                "category_list": {
                                    "category": {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "O1", 
                                                "@value": "2"
                                            }
                                        }
                                    }
                                }, 
                                "description": "Although positive clinical response criteria are based on RECIST criteria, failure to respond criteria are not based on RECIST criteria, which have unclear application to immune-based clinical trials. Instead, novel lack-of-failure criteria, rather than failure-of-success criteria have been written to avoid stopping therapy prematurely without compromising patient safety, to accommodate the uncertainties of assessing failure in this setting. The criteria as written are based on sound medical, scientific and ethical principles. The trial is further designed to help establish the utility of these novel criteria.", 
                                "param": "Number", 
                                "title": "Clinical Response Rate", 
                                "units": "participants"
                            }
                        ]
                    }, 
                    "safety_issue": "No", 
                    "time_frame": "every 3 months until the date of first documented progression or date of death from any cause, assessed up to 10 years", 
                    "title": "Clinical Response Rate", 
                    "type": "Primary"
                }
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Denileukin Diftitox Plus Subcutaneous Pegylated IFN\u03b1-2a :", 
                        "title": "Denileukin Diftitox Plus Subcutaneous Pegylated IFN\u03b1-2A"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": {
                                "participants_list": {
                                    "participants": {
                                        "@count": "2", 
                                        "@group_id": "P1"
                                    }
                                }, 
                                "title": "lack of funding"
                            }
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "2", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "0", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "2", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "pre_assignment_details": "Intercurrent illness that prevents further administration  of treatment\nUnacceptable adverse event(s)\nPatient withdraws from study\nGeneral or specific  changes in the patient's condition render the patient unacceptable for further treatment  in the judgment of the investigator.", 
                "recruitment_details": "This study was open to accrual on 7/29/2000 and closed to accrual on 6/27/2011.  Subjects were seen at The Cancer Therapy and Research Center @ The University of Texas Health Science Center San Antonio."
            }, 
            "point_of_contact": {
                "email": "CURIELT@UTHSCSA.EDU", 
                "name_or_title": "Tyler Curiel, MD", 
                "organization": "The Cancer and Therapy Center at The University of Texas Health Science Center San Antonio", 
                "phone": "210-562-5287"
            }
        }, 
        "completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Epithelial Ovarian Cancer", 
            "Extraovarian Peritoneal Cancer", 
            "Fallopian Tube Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Ovarian Neoplasms", 
                "Peritoneal Neoplasms", 
                "Fallopian Tube Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able to provide informed consent\n\n          -  Not on immune-modulating drugs, except those used as denileukin diftitox\n             premedication, unless the principal investigator grants an exception (which exception\n             must be documented in writing)\n\n          -  Histologically proven epithelial (non-germ cell, non-stromal cell) cancer of the\n             ovaries, fallopian tubes or extraovarian peritoneal carcinoma. Clinical recurrence\n             without documented pathology is acceptable\n\n          -  FIGO stage III or IV with failed prior first-line therapy, or ineligible for or\n             intolerant of such therapy\n\n          -  Measurable disease as defined in section 6 within 30 days of study enrollment\n\n          -  Blood hemoglobin \u2265 8.5 gm/dl within 7 days of study enrollment\n\n          -  Absolute neutrophil count \u2265 750/mm3 within 7 days of study enrollment\n\n          -  Platelet count \u2265 40,000/mm3 within 7 days of study enrollment\n\n          -  SGOT (serum glutamic oxaloacetic transaminase) \u226410 x upper limit of normal within 7\n             days of study enrollment\n\n          -  Normal TSH (thyroid-stimulating hormone ) within 30 days of study enrollment\n\n          -  No chemotherapy in the 14 days prior or radiation therapy in the thirty days prior to\n             initiation of treatment on this study\n\n          -  No other concurrent chemotherapy, surgery or radiation therapy during this protocol\n             except surgery or radiation therapy to control symptoms with concurrence of the\n             principal investigator\n\n          -  No contraindication to any study treatment\n\n          -  No active major medical problems, including untreated or uncontrolled infections\n\n          -  Beck Depression Index \u226515 within 30 days of study enrollment\n\n          -  If of reproductive potential, a negative urine pregnancy test within 3 days of study\n             enrollment, and agreement to use adequate contraception. Pregnancy testing will\n             continue monthly while on treatment unless the subject is no longer able to become\n             pregnant or there is sufficient justification otherwise\n\n          -  Not breast feeding\n\n          -  Life expectancy \u2265 six months\n\n          -  ECOG (Eastern Cooperative Oncology Group) performance status \u2264 2\n\n          -  Serum albumin \u2265 1.8 gm/dl\n\n          -  Age \u2265 18 years\n\n          -  Acceptable baseline retinal examination within 30 days of study enrollment\n\n          -  No active substance abuse in the prior 6 months\n\n          -  Patients failing single agent denileukin diftitox in the ongoing trial \"A Phase II\n             Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage\n             IV, or Extraovarian Peritoneal Carcinoma, Failing or Ineligible for First-Line\n             Therapy\" are eligible for this trial provided that three or more weeks have elapsed\n             since their last denileukin diftitox infusion and they meet all eligibility criteria\n             and successfully undergo all screening examinations for this trial.\n\n        Exclusion Criteria:\n\n          -  Unable to tolerate phlebotomy\n\n          -  Germ cell or stromal cell cancers of the ovaries, or other currently uncured cancer\n\n          -  Active autoimmune disease including systemic lupus erythematosus, psoriasis, or\n             inflammatory bowel disease that is not medically controlled\n\n          -  Autoimmune hepatitis, whether medically controlled or not\n\n          -  Contraindication to any study drug\n\n          -  Known hypersensitivity to denileukin diftitox, pegylated IFN-\u03b12a or any of their\n             components or excipients\n\n          -  Current pregnancy or breast feeding\n\n          -  Inability to document adequate contraception if a female of reproductive potential\n\n          -  On other immune-modulating drugs, except denileukin diftitox premedications or those\n             approved by the principal investigator\n\n          -  Chemotherapy within 14 days or radiation therapy within the thirty days prior to\n             initiation of study treatment\n\n          -  Life expectancy less than six months\n\n          -  Serum albumin < 1.8 gm/dl\n\n          -  Blood hemoglobin < 8.5 gm/dl\n\n          -  ECOG performance status> 2\n\n          -  Symptomatic coronary artery disease (including uncontrolled angina, congestive heart\n             failure, and the like)\n\n          -  Uncontrolled hypertension (diastolic BP consistently >100 mm Hg or systolic BP\n             consistently >160 mm Hg on a regular basis)\n\n          -  Uncontrolled, symptomatic cardiac arrhythmia\n\n          -  Retinopathy associated with significant visual impairment\n\n          -  Beck Depression Index >15\n\n          -  Active substance abuse in the prior 6 months"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 14, 2013", 
        "firstreceived_results_date": "May 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773889", 
            "org_study_id": "HSC20090233H", 
            "secondary_id": "OCR 09-01"
        }, 
        "intervention": {
            "arm_group_label": "Denileukin Diftitox Plus Subcutaneous Pegylated IFN\u03b1-2A", 
            "intervention_name": "Denileukin Diftitox Plus Subcutaneous Pegylated IFN\u03b1-2a", 
            "intervention_type": "Drug", 
            "other_name": "Ontak plus Pegylated IFN\u03b1-2a"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Denileukin diftitox", 
                "Interleukin-2"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Epithelial Ovarian Cancer", 
            "FIGO (International Federation of Gynecology and Obstetrics )Stage III or Stage IV", 
            "Extraovarian Peritoneal Cancer", 
            "Fallopian Tube Carcinoma Failing"
        ], 
        "lastchanged_date": "May 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78229"
                }, 
                "name": "CTRC (Cancer Therapy and Research Center) at UTHSCSA"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFN\u03b1-2a to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, or Fallopian Tube Carcinoma Failing Ineligible for First-Line Therapy (OCR 09-01)", 
        "overall_official": {
            "affiliation": "The University of Texas Health Science Center at San Antonio", 
            "last_name": "Tyler Curiel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Although positive clinical response criteria are based on RECIST criteria, failure to respond criteria are not based on RECIST criteria, which have unclear application to immune-based clinical trials. Instead, novel lack-of-failure criteria, rather than failure-of-success criteria have been written to avoid stopping therapy prematurely without compromising patient safety, to accommodate the uncertainties of assessing failure in this setting. The criteria as written are based on sound medical, scientific and ethical principles. The trial is further designed to help establish the utility of these novel criteria.", 
            "measure": "Clinical Response Rate", 
            "safety_issue": "No", 
            "time_frame": "every 3 months until the date of first documented progression or date of death from any cause, assessed up to 10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773889"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The University of Texas Health Science Center at San Antonio", 
            "investigator_full_name": "Tyler Curiel", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "The University of Texas Health Science Center at San Antonio", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tyler Curiel", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2009", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013", 
        "why_stopped": "Lack of funding"
    }
}